DA
Therapeutic Areas
EpiPharm Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Artemisinin-based Topical Formulation (Artemether) | Seborrhoeic Keratosis | Phase 2/3 |
| Artemisinin-based Topical Formulation | Melanocytic Lesions | Clinical-Stage |
| Proprietary Multi-Active Artemisia Composition | Prevention & Treatment of Dysplastic Epidermal Cell Growth | Preclinical/Clinical-Stage |